PTC Takes Over Fabry Gene Therapy in Potential $211 Million Deal as ST-920 Nears Filing Finish Line
Sangamo’s single-dose AAV therapy has already had portions of its U.S. marketing application submitted; PTC is betting not only on early clinical signals, but also on whether the manufacturing documentation can be completed in the fourth quarter and clear the most challenging regulatory hurdle for gene therapies.